Literature DB >> 25740088

Secondary prevention strategy of cardiovascular disease using endothelial function testing.

Yasushi Matsuzawa1, Raviteja R Guddeti, Taek-Geun Kwon, Lilach O Lerman, Amir Lerman.   

Abstract

Over the past decades, secondary prevention of cardiovascular (CV) disease has improved and considerably reduced mortality rates. However, there remains a high-rate of new or recurrent CV events in those with established atherosclerotic vascular diseases. Although most of the prevailing therapies target the conventional risk factors, there is notable interindividual heterogeneity in adaptation to risk factors and response to therapies, which affects efficacy. It is desirable to have a methodology for directly assessing the functional significance of atherogenesis, and for managing individual patients based on their comprehensive vascular health. Endothelial function plays a pivotal role in all stages of atherosclerosis, from initiation to atherothrombotic complication. Endothelial function reflects the integrated effect of all the atherogenic and atheroprotective factors present in an individual, and is therefore regarded as an index of active disease process and a significant risk factor for future CV events. Moreover, improvement in endothelial function is associated with decreased risk of CV events, even in the secondary prevention setting. The introduction of endothelial function assessment into clinical practice may trigger the development of a more tailored and personalized medicine and improve patient outcomes. In this review, we summarize current knowledge on the contribution of endothelial dysfunction to atherosclerotic CV disease in the secondary prevention setting. Finally, we focus on the potential of an endothelial function-guided management strategy in secondary prevention.

Entities:  

Mesh:

Year:  2015        PMID: 25740088     DOI: 10.1253/circj.CJ-15-0068

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  13 in total

Review 1.  Smoking cessation for secondary prevention of cardiovascular disease.

Authors:  Angela Difeng Wu; Nicola Lindson; Jamie Hartmann-Boyce; Azizia Wahedi; Anisa Hajizadeh; Annika Theodoulou; Elizabeth T Thomas; Charlotte Lee; Paul Aveyard
Journal:  Cochrane Database Syst Rev       Date:  2022-08-08

2.  Poly is more effective than monounsaturated fat for dietary management in the metabolic syndrome: The muffin study.

Authors:  Michael Miller; John D Sorkin; Laura Mastella; Aimee Sutherland; Jeffrey Rhyne; Patrick Donnelly; Kathy Simpson; Andrew P Goldberg
Journal:  J Clin Lipidol       Date:  2016-05-06       Impact factor: 4.766

3.  Antioxidant Properties of Novel Dimers Derived from Natural β-Elemene through Inhibiting H2O2-Induced Apoptosis.

Authors:  Jichao Chen; Ruifan Wang; Tianyu Wang; Qilong Ding; Aliahmad Khalil; Shengtao Xu; Aijun Lin; Hequan Yao; Weijia Xie; Zheying Zhu; Jinyi Xu
Journal:  ACS Med Chem Lett       Date:  2017-03-13       Impact factor: 4.345

4.  Rheumatoid arthritis significantly increased recurrence risk after ischemic stroke/transient ischemic attack.

Authors:  Yih-Ru Chen; Fang-I Hsieh; Li-Ming Lien; Chaur-Jong Hu; Jiann-Shing Jeng; Giia-Sheun Peng; Sung-Chun Tang; Nai-Fang Chi; Yueh-Feng Sung; Hung-Yi Chiou
Journal:  J Neurol       Date:  2018-06-02       Impact factor: 4.849

5.  IL-6 Response to Psychosocial Stress Predicts 12-month Changes in Cardiometabolic Biomarkers in Perimenopausal Women.

Authors:  Anthony S Zannas; Jennifer L Gordon; Alan L Hinderliter; Susan S Girdler; David R Rubinow
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

6.  The Relationship between Endothelial Dysfunction and Endothelial Cell Markers in Peripheral Arterial Disease.

Authors:  Kimihiro Igari; Toshifumi Kudo; Takahiro Toyofuku; Yoshinori Inoue
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

7.  Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.

Authors:  Atsushi Tanaka; Michio Shimabukuro; Yosuke Okada; Isao Taguchi; Minako Yamaoka-Tojo; Hirofumi Tomiyama; Hiroki Teragawa; Seigo Sugiyama; Hisako Yoshida; Yasunori Sato; Atsushi Kawaguchi; Yumi Ikehara; Noritaka Machii; Tatsuya Maruhashi; Kosuke R Shima; Toshinari Takamura; Yasushi Matsuzawa; Kazuo Kimura; Masashi Sakuma; Jun-Ichi Oyama; Teruo Inoue; Yukihito Higashi; Shinichiro Ueda; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2017-04-12       Impact factor: 9.951

Review 8.  Prognostic Value of Flow-Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta-Analysis.

Authors:  Yasushi Matsuzawa; Taek-Geun Kwon; Ryan J Lennon; Lilach O Lerman; Amir Lerman
Journal:  J Am Heart Assoc       Date:  2015-11-13       Impact factor: 5.501

9.  The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.

Authors:  Seigo Sugiyama; Hideaki Jinnouchi; Noboru Kurinami; Kunio Hieshima; Akira Yoshida; Katsunori Jinnouchi; Hiroyuki Nishimura; Tomoko Suzuki; Fumio Miyamoto; Keizo Kajiwara; Tomio Jinnouchi
Journal:  Intern Med       Date:  2018-03-30       Impact factor: 1.271

10.  Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.

Authors:  Atsushi Tanaka; Michio Shimabukuro; Yosuke Okada; Kazuhiro Sugimoto; Akira Kurozumi; Keiichi Torimoto; Hiroyuki Hirai; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2020-06-13       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.